Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers

NCT03112733UNKNOWNOBSERVATIONAL

Summary

Key Facts

Lead Sponsor

Ilker Kahramanoglu

Enrollment

171

Start Date

2017-04-04

Completion Date

2018-06-21

Study Type

OBSERVATIONAL

Official Title

Value of TFF3, SFRP4, Romo1 and NFKB as Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers

Interventions

TFF3SFRP4Romo1NFKB

Conditions

Endometrial NeoplasmsOvarian Neoplasms

Eligibility

Age Range

18 Years – 70 Years

Sex

FEMALE

Inclusion Criteria:

* Primary diagnosis of epithelial ovarian carcinoma.

Exclusion Criteria:

* Patients with recurrence.
* Patients who received neoadjuvant chemotherapy or radiotherapy
* Presence of any secondary malignancy

Outcome Measures

Primary Outcomes

Efficacy of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-Κb in discrimination of benign and malignant gynecologic disease

To measure serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB between groups and to identify a possible significant diagnostic marker

Time frame: 2 days

Secondary Outcomes

Efficacy of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-Κb in predicting overall survival and disease-free survival

To determine any relationship between prognosis of ovarian cancer and serum levels of four different biomarkers

Time frame: 1 year

Locations

Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey (Türkiye)